Open original FDA record ↗Recall record
- FDA identifier
- Z-1073-2017
- Company in FDA record
- The Binding Site Group, Ltd.
- FDA classification date
- Jan 23, 2017
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Customer complaints identified that samples containing extremely high IgG4 levels exhibit antigen excess and will yield spuriously low IgG4 results.
Source facts
- Action
- Binding Site sent an Important Information letter dated September 30, 2014, Customers were instructed to retain the notification for records and additional instructions with the firm stating they were updating the instructions for use. Customers with questions were advised to contact their Binding Site representative or technical.service@bindingsite.co.uk.
- Initiated
- 2014-09-11
- Root cause
- Nonconforming Material/Component
- Terminated
- 2017-05-03
- Distribution
- Worldwide Distribution - US including n FL, OH, TN, MN, NW, MI, CA. and Internationally to Canada, France, UK, Spain, Germany, Czech Republic, Belgium, Italy, Australia, Brazil, Chile, China, Costa Rica, Kuwait, New Zealand, Oman, Pakistan, Portugal, Sweded, Taiwan, and Turkey.
- Recall number
- Z-1073-2017
- Recall status
- Terminated
- CDRH record ID
- 152037
- FDA classified
- 2017-01-23
- Recall event number
- 76041